Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Front Pediatr ; 12: 1363576, 2024.
Article in English | MEDLINE | ID: mdl-38601274

ABSTRACT

Background: Programs that aim to improve the detection hypoxic-ischemic encephalopathy (HIE) should establish which neonates suffering from perinatal asphyxia need to be monitored within the first 6 h of life. Method: An observational prospective cohort study of infants with gestational age ≥35 weeks, and above 1,800g, were included according to their arterial cord pH value (ApH): ≤7.00 vs. 7.01-7.10. Data was collected including obstetrical history, as well as neonatal comorbidities, including the presence of HIE, that happened within 6 h of life. A standardized neurological exam was performed at discharge. Results: There were 9,537 births; 176 infants with ApH 7.01-7.10 and 117 infants with ApH ≤7.00. All 9 cases with moderate-to-severe HIE occurred among infants with ApH ≤7.00. The incidence of global and moderate-severe HIE was 3/1,000 and 1/1,000 births, respectively. Outcome at discharge (abnormal exam or death) showed an OR 12.03 (95% CI 1.53, 94.96) in infants with ApH ≤7.00 compared to ApH 7.01-7.10 cohort. Ventilation support was 5.1 times (95% CI 2.87, 9.03) more likely to be needed by those with cord ApH ≤7.00 compared to those with ApH 7.01-7.10, as well as hypoglycemia (37% vs. 25%; p = 0.026). In 55%, hypoglycemia occurred despite oral and/or intravenous glucose administration had been already initiated. Conclusions: Cord pH 7.00 might be a safe pH cut-off point when developing protocols to monitor infants born with acidemia in order to identify infants with moderate or severe HIE early on. There is non-negligible comorbidity in the ApH ≤7.00 cohort, but also in the 7.01-7.10 cohort.

2.
An. pediatr. (2003. Ed. impr.) ; 98(5): 338-343, may. 2023. ilus, tab, graf
Article in Spanish | IBECS | ID: ibc-220071

ABSTRACT

Introducción: El objetivo fue establecer valores de normalidad de antitrombina (AT), la proteína C (PC) y la proteína S (PS) dentro de la primera semana después del nacimiento en el binomio madre-recién nacido, ajustados por factores obstétricos y perinatales, según 2 métodos de laboratorio diferentes. Métodos: Se realizaron determinaciones en 83 neonatos a término sanos y sus madres, con 3 grupos de edad posparto: días 1-2, 3 y 4-7. Resultados :No hubo diferencias para ninguna de las proteínas en los distintos grupos de edad de los neonatos y las madres dentro de la primera semana posparto. El análisis ajustado no mostró ninguna asociación con factores obstétricos o perinatales. Los valores de AT y PC en las madres fueron mayores que en los neonatos (p<0,001), mientras que la PS mostró valores similares. La correlación global de los valores entre los pares madre-recién nacido fue escasa, salvo para la PS libre en los en los siguientes 2 días al parto. Aunque no se encontraron diferencias entre los 2 métodos de laboratorio, los valores absolutos fueron diferentes. (AU)


Introduction: The objective of the study was to establish the normal range for the levels of antithrombin (AT), protein C (PC), and protein S (PS) in the first week post birth in mother-infant dyads, adjusting for obstetric and perinatal factors, based on 2 different laboratory methods. Methods: We took measurements in 83 healthy term neonates and their mothers, establishing 3 postpartum age groups: 1-2 days, 3 days, and 4-7 days. Results: There were no differences in the levels of any of the proteins between the different age groups in neonates or mothers in the first week post birth. The adjusted analysis found no association with obstetric or perinatal factors. The AT and PC levels were higher in mothers compared to infants (P<.001), while the PS levels were similar in both. Overall, the correlation of maternal and infant protein values was poor, except for the levels of free PS in the first 2 days post birth. Although we found no differences based on which of the 2 laboratory methods was applied, the absolute values did differ. (AU)


Subject(s)
Humans , Male , Female , Infant, Newborn , Antithrombins , Protein C , Protein S , Mother-Child Relations , Postpartum Period
3.
An Pediatr (Engl Ed) ; 98(5): 338-343, 2023 May.
Article in English | MEDLINE | ID: mdl-37076369

ABSTRACT

INTRODUCTION: The objective of the study was to establish the normal range for the levels of antithrombin (AT), protein C (PC), and protein S (PS) in the first week post birth in mother-infant pairings, adjusting for obstetric and perinatal factors, based on 2 different laboratory methods. METHODS: Determinations were carried out in 83 healthy term neonates and their mothers, establishing 3 postpartum age groups: 1-2 days, 3 days, and 4-7 days. RESULTS: There were no differences in the levels of any of the proteins between the different age groups in neonates or mothers in the first week post birth. The adjusted analysis found no association with obstetric or perinatal factors. The AT and PC levels were higher in mothers compared to infants (P < .001), while the PS levels were similar in both. Overall, the correlation of maternal and infant protein values was poor, except for the levels of free PS in the first 2 days after delivery. Although we found no differences based on which of the 2 laboratory methods was applied, the absolute values did differ.


Subject(s)
Mothers , Protein C , Child, Preschool , Female , Humans , Infant , Infant, Newborn , Pregnancy , Postpartum Period , Thrombin , Protein S , Antithrombins
4.
Neuropediatrics ; 52(3): 192-200, 2021 06.
Article in English | MEDLINE | ID: mdl-33657631

ABSTRACT

OBJECTIVE: The study aimed to describe the cases of neurological disease related to the outbreak of enterovirus (EV) in three regions in Northern Spain during 2016. MATERIALS AND METHODS: Multicenter retrospective observational study. Clinical, radiological, and microbiological data were analyzed from patients younger than 15 years with confirmed EV-associated neurological disease admitted to 10 hospitals of Asturias, Cantabria, and Castile and Leon between January 1 and December 31, 2016. RESULTS: Fifty-five patients were included. Median age was 24 months (interquartile range = 18.5 months). Fifteen patients were classified as aseptic meningitis (27.3%). In total, 37 cases presented brainstem encephalitis (67.3%), 25 of them due to EV-A71 with excellent prognosis (84.6% asymptomatic 2 months following the onset). Three cases of acute flaccid myelitis (5.5%) by EV-D68 were reported and presented persistent paresis 2 months following the onset. Microbiological diagnosis by reverse transcriptase polymerase chain reaction was performed in all cases, finding EV in cerebrospinal fluid in meningitis, but not in brainstem encephalitis and acute flaccid myelitis, where EV was found in respiratory or rectal samples. Step therapy was administrated with intravenous immunoglobulin (IVIG; 32.7%), methylprednisolone (10%), and plasmapheresis (3.6%). Four patients received fluoxetine (7.3%). Twenty patients needed to be admitted to pediatric intensive care unit (36.4%). CONCLUSION: Clinical, microbiological, and radiological diagnosis is essential in outbreaks of EV neurological disease, taking into account that it can be difficult to identify EV-A71 and EV-D68 in CSF, requiring throat or rectal samples. There is not specific treatment to these conditions and the efficacy and understanding of the mechanism of action of immune-modulatory treatment (IVIG, corticosteroids, and plasmapheresis) is limited.


Subject(s)
Enterovirus D, Human , Enterovirus Infections , Myelitis , Child , Disease Outbreaks , Enterovirus Infections/diagnosis , Enterovirus Infections/epidemiology , Enterovirus Infections/therapy , Humans , Infant , Myelitis/complications , Myelitis/epidemiology , Myelitis/therapy , Spain/epidemiology
5.
Infection ; 48(3): 463-469, 2020 Jun.
Article in English | MEDLINE | ID: mdl-32125680

ABSTRACT

Treatment of congenital cytomegalovirus infection is mandatory in cases with severe systemic and/or neurological involvement. However, some patients are paucisymptomatic, with very subtle systemic manifestations and/or minimal brain alterations. Current international guidelines do not clearly state whether these children should be treated, and this decision is not straightforward for clinicians. Of a small series of six infants with congenital cytomegalovirus infection admitted to our neonatal unit between 2015 and 2019, half showed paucisymptomatic neurological manifestations. In these cases, the determination of ß2-microglobulin in cerebrospinal fluid and magnetic resonance imaging aided in the decision-making concerning the therapeutic approach to follow.


Subject(s)
Brain/diagnostic imaging , Cytomegalovirus Infections/diagnosis , beta 2-Microglobulin/cerebrospinal fluid , Antiviral Agents/therapeutic use , Cytomegalovirus/physiology , Cytomegalovirus Infections/congenital , Cytomegalovirus Infections/diagnostic imaging , Cytomegalovirus Infections/drug therapy , Female , Humans , Infant , Infant, Newborn , Magnetic Resonance Imaging , Male , Spain , Valganciclovir/therapeutic use
6.
Clin Appl Thromb Hemost ; 25: 1076029619834352, 2019.
Article in English | MEDLINE | ID: mdl-31025572

ABSTRACT

Little is known about the pathogenesis of cerebral sinovenous thrombosis (CSVT) in the neonate. Although thrombophilia has been described as increasing the risk of CSVT in adults, it remains controversial in pediatric patients, and prospective case-control studies regarding neonatal CSVT are lacking. From 2008 to 2017, all 26 consecutive newborn infants ≥35 weeks of gestation diagnosed with neonatal CSVT, and their mothers, were tested for factor V Leiden (FV) G1691A, FII G20210A, and methylenetetrahydrofolate reductase C677T (MTHFR C677T) mutations. Eighty-five mother-infant pairs were recruited as controls. All infants except 1 with CSVT were suspected due to clinical symptoms, mainly seizures (22/25). Magnetic resonance imaging was performed in 24/26 infants. Heterozygous FV G1691A, FII G20210A, and homozygous MTHFR C677T mutations were present in 1/26, 3/26, and 3/20 infants with CSVT, respectively. FII (odds ratio: 10.96; 95% confidence interval [CI]: 1.09-110.35) and male sex (3.93; 95% CI: 1.43-10.76) were associated with CSVT. When FII G20210A analysis was adjusted for sex, the OR for FII G20210A was 6.70 (95% CI: 0.65-69.22). No differences were found for FV G1691A or homozygous MTHFR mutations between neonates with CSVT and their mothers, compared to controls.


Subject(s)
Factor V/genetics , Genetic Diseases, Inborn/genetics , Intracranial Thrombosis/genetics , Methylenetetrahydrofolate Reductase (NADPH2)/genetics , Mutation, Missense , Prothrombin/genetics , Adult , Female , Heterozygote , Humans , Infant, Newborn , Male , Prospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...